A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer

[1]  D. Moore,et al.  A COP1-GATA2 axis suppresses AR signaling and prostate cancer , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[2]  V. Gorgoulis,et al.  Interplay of Developmental Hippo–Notch Signaling Pathways with the DNA Damage Response in Prostate Cancer , 2022, Cells.

[3]  G. Haas,et al.  Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  V. Gorgoulis,et al.  CRISPR-Cas9-mediated induction of large chromosomal inversions in human bronchial epithelial cells , 2022, STAR protocols.

[5]  R. Bernards,et al.  Exploiting senescence for the treatment of cancer , 2022, Nature Reviews Cancer.

[6]  B. Stripp,et al.  Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis , 2022, European Respiratory Journal.

[7]  M. Vinciguerra,et al.  The costs and benefits of senotherapeutics for human health. , 2022, The Lancet. Healthy longevity.

[8]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[9]  Daniela Pankova,et al.  RASSF1A disrupts the NOTCH signaling axis via SNURF/RNF4‐mediated ubiquitination of HES1 , 2021, EMBO reports.

[10]  Jinpeng Liu,et al.  Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer , 2021, Molecular Cancer Therapeutics.

[11]  D. H. Larsen,et al.  A recurrent chromosomal inversion suffices for driving escape from oncogene-induced senescence via subTAD reorganization. , 2021, Molecular cell.

[12]  O. Hazapis,et al.  The Role of Circular RNAs in DNA Damage Response and Repair , 2021, Cancers.

[13]  M. Stockler,et al.  Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase , 2021, EBioMedicine.

[14]  D. Gewirtz,et al.  Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy. , 2021, Biochemical pharmacology.

[15]  V. Gorgoulis,et al.  Regulatory and Functional Involvement of Long Non-Coding RNAs in DNA Double-Strand Break Repair Mechanisms , 2021, Cells.

[16]  J. Campisi,et al.  Algorithmic assessment of cellular senescence in experimental and clinical specimens , 2021, Nature Protocols.

[17]  Z. Trajanoski,et al.  MYC-mediated ribosomal gene expression sensitizes enzalutamide-resistant prostate cancer cells to EP300/CREBBP inhibitors. , 2021, The American journal of pathology.

[18]  S. Lavrentiadou,et al.  Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells , 2021, Breast Cancer Research and Treatment.

[19]  V. Gorgoulis,et al.  Non-Canonical Functions of the ARF Tumor Suppressor in Development and Tumorigenesis , 2021, Biomolecules.

[20]  M. Tsolaki,et al.  Restoration of BMI1 levels after the administration of early harvest extra virgin olive oil as a therapeutic strategy against Alzheimer's disease , 2020, Experimental Gerontology.

[21]  Laura M. Heiser,et al.  Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease , 2020, Scientific Reports.

[22]  G. MacLennan,et al.  Androgen Deprivation Induces Transcriptional Reprogramming in Prostate Cancer Cells to Develop Stem Cell-Like Characteristics , 2020, International journal of molecular sciences.

[23]  Sanjay Gupta,et al.  Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer , 2020, Cells.

[24]  V. Gottifredi,et al.  Under-Replicated DNA: The Byproduct of Large Genomes? , 2020, Cancers.

[25]  A. Blanco,et al.  Senolytic activity of small molecular polyphenols from olive restores chondrocyte redifferentiation and promotes a pro-regenerative environment in osteoarthritis , 2020, Aging.

[26]  J. Kirkland,et al.  Senolytic drugs: from discovery to translation , 2020, Journal of internal medicine.

[27]  J. Yuen,et al.  Comparative study of surgical orchidectomy and medical castration in treatment efficacy, adverse effects and cost based on a large prospective metastatic prostate cancer registry. , 2020, Urologic oncology.

[28]  C. Schmitt,et al.  Cellular Senescence: Defining a Path Forward , 2019, Cell.

[29]  C. Robson,et al.  The Pioneering Role of GATA2 in Androgen Receptor Variant Regulation Is Controlled by Bromodomain and Extraterminal Proteins in Castrate-Resistant Prostate Cancer , 2019, Molecular Cancer Research.

[30]  Julian Spies,et al.  53BP1 nuclear bodies enforce replication timing at under-replicated DNA to limit heritable DNA damage , 2019, Nature Cell Biology.

[31]  G. Scagliotti,et al.  Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions , 2018, OncoTargets and therapy.

[32]  P. Nelson,et al.  Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. , 2018, Cancer research.

[33]  H. G. van der Poel,et al.  Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond , 2018, Endocrine-related cancer.

[34]  Lunquan Sun,et al.  Radiation-promoted CDC6 protein stability contributes to radioresistance by regulating senescence and epithelial to mesenchymal transition , 2018, Oncogene.

[35]  M. Demaria,et al.  Hallmarks of Cellular Senescence. , 2018, Trends in cell biology.

[36]  Alexander Kanapin,et al.  RASSF1A uncouples Wnt from Hippo signalling and promotes YAP mediated differentiation via p73 , 2018, Nature Communications.

[37]  Jiri Bartek,et al.  A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence , 2018, BMC Genomics.

[38]  Wei Zhang,et al.  Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. , 2017, Cell reports.

[39]  Dimitris Kletsas,et al.  Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing , 2016, Nature Cell Biology.

[40]  V. Gorgoulis,et al.  Systemic dna damage: Mechanisms, effects and mitigation strategies. , 2016, Seminars in cancer biology.

[41]  R. Karnes,et al.  Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer , 2016, Oncotarget.

[42]  A. Pezeshki,et al.  Naturally occurring p16Ink4a-positive cells shorten healthy lifespan , 2016, Nature.

[43]  Jindan Yu,et al.  FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression , 2016, Oncogene.

[44]  H. Erb,et al.  Therapy escape mechanisms in the malignant prostate. , 2015, Seminars in cancer biology.

[45]  M. Gleave,et al.  Targeting the adaptive molecular landscape of castration-resistant prostate cancer , 2015, EMBO molecular medicine.

[46]  M. Gleave,et al.  The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors , 2015, International journal of cancer.

[47]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[48]  S. Dudoit,et al.  Normalization of RNA-seq data using factor analysis of control genes or samples , 2014, Nature Biotechnology.

[49]  Paul Theodor Pyl,et al.  HTSeq – A Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[50]  T. Thompson,et al.  Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches , 2013, Oncogene.

[51]  M. Jordá,et al.  Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells , 2013, PloS one.

[52]  Wei Huang,et al.  Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo , 2013, The Prostate.

[53]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[54]  Aristides G. Eliopoulos,et al.  Cdc6 expression represses E-cadherin transcription and activates adjacent replication origins , 2011, The Journal of cell biology.

[55]  N. LeBrasseur,et al.  Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders , 2011, Nature.

[56]  G. Jenster,et al.  Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell Models , 2010, PloS one.

[57]  I. Petersen,et al.  Cellular senescence predicts treatment outcome in metastasised colorectal cancer , 2010, British Journal of Cancer.

[58]  J. Fondell,et al.  A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression , 2009, Nucleic acids research.

[59]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[60]  M. Narita,et al.  SASP reflects senescence , 2009, EMBO reports.

[61]  Bruce Montgomery,et al.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion , 2009, Nature Clinical Practice Urology.

[62]  Jiri Bartek,et al.  An Oncogene-Induced DNA Damage Model for Cancer Development , 2008, Science.

[63]  Dimitris Kletsas,et al.  Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. , 2007, Cancer research.

[64]  Aaron Bensimon,et al.  Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication , 2006, Nature.

[65]  Dimitris Kletsas,et al.  Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints , 2006, Nature.

[66]  H. Klocker,et al.  Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[67]  Vassilis G Gorgoulis,et al.  Overexpression of the replication licensing regulators hCdt1 and hCdc6 characterizes a subset of non-small-cell lung carcinomas: synergistic effect with mutant p53 on tumor growth and chromosomal instability--evidence of E2F-1 transcriptional control over hCdt1. , 2004, The American journal of pathology.

[68]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[69]  R K Valicenti,et al.  Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  G. Peters,et al.  Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts , 1998, Current Biology.

[71]  L. Chung,et al.  Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. , 1994, Cancer research.

[72]  Schr,et al.  Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. , 1994, The American journal of pathology.

[73]  J. Lechner,et al.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3). , 1979, Investigative urology.

[74]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[75]  Alexander Kanapin,et al.  RASSF1A uncouples Wnt from Hippo signalling and promotes YAP mediated differentiation via p73 , 2018, Nature Communications.

[76]  C. Cordon-Cardo,et al.  The role of GATA2 in lethal prostate cancer aggressiveness , 2017, Nature Reviews Urology.

[77]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[78]  F. Saad,et al.  Enzalutamide in Metastatic Prostate Cancer before Chemotherapy , 2014 .

[79]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[80]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[81]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[82]  R. Sutherland,et al.  Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. , 2001, Cancer research.

[83]  J. A. van der Korput,et al.  The human androgen receptor: domain structure, genomic organization and regulation of expression. , 1989, Journal of steroid biochemistry.